Evaluation of NEUROG1 methylation status in stool specimens in the advanced adenomas and colorectal cancer

Background To assess the status of NEUROG1 methylation in the advanced adenoma and colorectal cancer. Methods The NEUROG1 methylation in tissue and stool samples from patients with colorectal cancer (CRC), advanced adenoma (AA), and non-advanced adenoma (NAA) were evaluated using methylation-specifi...

Full description

Bibliographic Details
Published in:PeerJ
Main Authors: Lijin Zhang, Aiping Lin, Jie Lin, Juan Chen, Mengshi Chen, Xunbin Yu, Yijuan Wu, Tao Wang, Yan Lu, Zhaofen Ba, Xiaowei Cheng, Tiantian Zhang, Minghong Chen
Format: Article
Language:English
Published: PeerJ Inc. 2025-10-01
Subjects:
Colorectal cancer
NEUROG1
Stool
DNA methylation
Diagnosis
Online Access:https://peerj.com/articles/19968.pdf
Description
Summary:Background To assess the status of NEUROG1 methylation in the advanced adenoma and colorectal cancer. Methods The NEUROG1 methylation in tissue and stool samples from patients with colorectal cancer (CRC), advanced adenoma (AA), and non-advanced adenoma (NAA) were evaluated using methylation-specific quantitative polymerase chain reaction (PCR). Results In tissue samples, the NEUROG1 methylation detection rates were 36% for CRC, 24% for NAA, and 88% for AA. In stool samples, the NEUROG1 methylation detection had a sensitivity of 63.46% for CRC with a positive predictive value (PPV) of 85.94%. The overall diagnostic specificity of the test for the NAA and the healthy control was 76.32%, with a negative predictive value (NPV) of 40.28%. Conclusion NEUROG1 methylation detection can potentially be used in the CRC and AA screening.
ISSN:2167-8359

Similar Items